Publication
, Journal Article
Morse, MA; Osada, T; Hobeika, A; Patel, S; Lyerly, HK
Published in: American Society of Clinical Oncology Educational Book
May 2013
American Society of Clinical Oncology Educational Book
1548-8756
1548-8748
May 2013
33
e287 / e293
American Society of Clinical Oncology (ASCO)
APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., Osada, T., Hobeika, A., Patel, S., & Lyerly, H. K. (2013). Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types? American Society of Clinical Oncology Educational Book, (33), e287–e293. https://doi.org/10.14694/edbook_am.2013.33.e287
Morse, Michael A., Takuya Osada, Amy Hobeika, Sandip Patel, and H Kim Lyerly. “Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?” American Society of Clinical Oncology Educational Book, no. 33 (May 2013): e287–93. https://doi.org/10.14694/edbook_am.2013.33.e287.
Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK. Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types? American Society of Clinical Oncology Educational Book. 2013 May;(33):e287–93.
Morse, Michael A., et al. “Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?” American Society of Clinical Oncology Educational Book, no. 33, American Society of Clinical Oncology (ASCO), May 2013, pp. e287–93. Crossref, doi:10.14694/edbook_am.2013.33.e287.
Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK. Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology (ASCO); 2013 May;(33):e287–e293.
American Society of Clinical Oncology Educational Book
1548-8756
1548-8748
May 2013
33
e287 / e293
American Society of Clinical Oncology (ASCO)